Systematic Review and Meta-Analysis: Macrolides- and Amoxicillin/Clavulanate-induced Acute Liver Injury

Basic and Clinical Pharmacology and Toxicology

Volumn 119, Issue 1, 2016, Pages 3-9

  Ferrer, Pili ^a   Amelio, Justyna ^b   Ballarín, Elena ^a,c,d   Sabaté, Mònica ^a,c,d   Vidal, Xavi ^a,c,d   Rottenkolber, Marietta ^e   Schmiedl, Sven ^f,g   Laporte, Joan Ramon ^a,c,d   Ibáñez, Luisa ^a,c,d  

^a Fundacion Institut Catala de Farmacologia   (Spain)

^b AMGEN LTD   (United Kingdom)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e UNIVERSITY OF MUNICH   (Germany)

^f University Hospital Witten Herdecke   (Germany)

^g UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; MACROLIDE; AMOXICILLIN; CLAVULANIC ACID;

ARTICLE; CHECKLIST; COCHRANE LIBRARY; HUMAN; MEDICAL SUBJECT HEADINGS; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW; TOXIC HEPATITIS; WEB OF SCIENCE; ADVERSE DRUG REACTION; DRUG EFFECTS; FACTUAL DATABASE; LIVER; PATHOLOGY;

AMOXICILLIN; CHEMICAL AND DRUG INDUCED LIVER INJURY; CLAVULANIC ACID; DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; LIVER; MACROLIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84992289575     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12550     Document Type: Article

References (43)

1. Bell L, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis 2009;29:337-47.
2. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of the available epidemiological data. J Hepatol 2013;58:593-608.
3. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005;42:481-9.
4. Zimmerman HK. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, 1999.
5. Andrade RJ, Lucena MI, Fernández MC, Peláez C, PachkoriaK García-Ruíz E et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology 2005;129:512-21.
6. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J et al. Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009;32:55-68.
7. Chang CY, Schiano TD. Review article: drug hepatotoxicity. Aliment Pharmacol Ther 2007;10:1135-51.
8. Stine JG, Lewis JH. Hepatotoxicity of antibiotics: a review and update for the clinician. Clin Liv Dis 2013;17:609-42.
9. Ferech M, Coenen S, Malhotra-Kumar S, Dvorakova K, Hendrickx E, Suetens C et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe. J Antimicrob Chemother 2006;58:401-7.
10. Matuz M, Bognar J, Hajdu E, Doro P, Bor A, Viola R et al. Treatment of community-acquired pneumonia in adults: analysis of the national dispensing database. Basic Clin Pharmacol Toxicol 2015;117:330-4.
11. Abbing-Karahagopian V, Kurz X, Vries F, van Staa T, Alvarez Y, Hesse U et al. Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT project. Curr Clin Pharmacol 2014;9:130-8.
12. Bénichou C. Criteria of drug-induced hepatic disorders. Report on an International Consensus Meeting. J Hepatol 1990;11:272-6.
13. European Medicines Agency. Committee for Medicinal Products for Human Use. Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical. and one or more established medicines are available. EMA/759784/2010. November 2010.
14. Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008;47:2003-9.
15. Ferrer P, Ballarín E, Sabaté M, Vidal X, Rottenkolber M, Amelio J et al. Antiepileptic drugs and suicide: a systematic review of adverse effects. Neuroepidemiology 2014;42:107-20.
16. Rottenkolber M, Rottenkolber D, Fischer R, Ibáñez L, Fortuny J, Ballarin E et al. Inhaled beta-2-agonists/muscarinic antagonists and acute myocardial infarction in COPD patients. Respir Med 2014;108:1075-90.
17. Kirkwood BR, Sterne JAC. Comparing two proportions. Essential Medical Statistics, 2nd edn. Blackwell Science Ltd, Oxford, 2003; 148-64.
18. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
19. Palmer T, Peters J, Sutton A, Moreno S. Contour-enhanced funnel plots for meta-analysis. Stata J 2008;8:242-54.
20. Kamada AK, Hill MR, Iklé DN, Brenner AM, Szefler SJ. Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin Immunol 1993;91:873-82.
21. Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, Nieman RB. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006;354:1589-600.
22. De Abajo FJ, Montero D, Madurga M, García-Rodríguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004;58:71-80.
23. Carson JL, Strom BL, Duff A, Gupta A, Das K, Shaw M et al. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med 1993;119:576-83.
24. Derby LE, Jick H, Henry DA, Dean AD. Erythromycin-associated cholestatic hepatitis. Med J Aust 1993;158:600-2.
25. Lee C-H, Wang J-D, Chen P-C. Case-crossover design: an alternative strategy for detecting drug-induced liver injury. J Clin Epidemiol 2012;65:560-7.
26. Kaye JA, Castellsague J, Bui CL, Calingaert B, McQuay LJ, Riera-Guardia N et al. Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study. Pharmacotherapy 2014;34:336-49.
27. Pérez Gutthann S, García Rodríguez LA. The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology 1993;4:496-501.
28. Maggini M, Raschetti R, Agostinis L, Cattaruzzi C, Troncon MG, Simon G. Use of amoxicillin and amoxicillin-clavulanic acid and hospitalization for acute liver injury. Ann Ist Super Sanita 1999;35:429-33.
29. Sabaté M, Ibáñez L, Pérez E, Vidal X, Buti M, Xiol X et al. Risk of acute liver injury associated with the use of drugs: a multicentre population survey. Aliment Pharmacol Ther 2007;25:1401-9.
30. Théophile H, Laporte JR, Moore N, Martin KL, Bégaud B. The case-population study design: an analysis of its application in pharmacovigilance. Drug Saf 2011;34:861-8.
31. Salvo F, Polimeni G, Moretti U, Conforti A, Leone R, Leoni O et al. Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. J Antimicrob Chemother 2007;60:121-6.
32. Dore DD, DiBello JR, Lapane KL. Telithromycin use and spontaneous reports of hepatotoxicity. Drug Saf 2007;30:697-703.
33. Ferrajolo C, Capuano A, Verhamme KMC, Schuemie M, Rossi F, Stricker BH et al. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. Br J Clin Pharmacol 2010;70:721-8.
34. Ferrajolo C, Coloma PM, Verhamme KMC, Schuemie MJ, de Bie S, Gini R et al. Signal detection of potentially drug-induced acute liver injury in children using a multi-country healthcare database network. Drug Saf 2014;37:99-108.
35. Brauer R, Ruigómez A, Klungel O, Reynolds R, Feudjo Tepie M, Smeeth L et al. The risk of acute liver injury among users of antibiotic medications: a comparison of case-only studies. Pharmacoepidemiol Drug Saf 2015; [Internet]. doi:http://doi.wiley.com/10.1002/pds.3846.
36. Udo R, Tcherny-Lessenot S, Brauer R, Dolin P, Irvine D, Wang Y et al. The risk of acute liver injury associated with the use of antibiotics-evaluating robustness of results in the pharmacoepidemiological research on outcomes of therapeutics by a European consortium (PROTECT) project. Pharmacoepidemiol Drug Saf 2015; [Internet]. doi:http://doi.wiley.com/10.1002/pds.3841.
37. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014;109:950-66.
38. Chalasani N, Björnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010;138:2246-59.
39. Brinker AD, Wassel RT, Lydly J, Serrano J, Avigan M, Lee WM et al. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 2009;49:250-7.
40. Lucena MI, Andrade RJ, Fernández MC, Pachkoria K, Peláez G, Durán JA et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 2006;44:850-6.
41. Golder S, Loke Y, Bland M. Randomised controlled trials as compared to observational studies: methodological overview. PLoS Med 2011;8:e1001026. doi:10.1371/journal.pmed.1001026.
42. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011;89:806-15.
43. Malo S, Rabaneque MJ, Feja C, Lallana MJ, Aguilar I, Bjerrun L. High antibiotic consumption: a characterization of heavy users in Spain. Basic Clin Pharmacol Toxicol 2014;115:231-6.